Granules India Ltd Stock Price Today (NSE: GRANULES)
Fundamental Score
Granules India Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Granules India Ltd share price today is ₹620.40, down 0.75% on NSE/BSE as of 30 March 2026. Granules India Ltd (GRANULES) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹13.79K (Cr). The 52-week high for GRANULES share price is ₹640.00 and the 52-week low is ₹422.00. At a P/E ratio of 27.00x, GRANULES is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 13.86% and a debt-to-equity ratio of 0.45.
Granules India Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Granules India Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Granules Share Price: A Conservative Value Investor's Perspective
The pharmaceutical industry, while inherently defensive due to consistent healthcare demand, requires careful navigation. Patent cliffs, regulatory hurdles, and intense competition can significantly impact profitability. This analysis offers a conservative value investor's perspective on Granules share price (₹563.700012), focusing on capital safety and long-term value.
Currently trading at a PE ratio of 27.0, Granules India Ltd needs scrutiny. A high PE ratio isn't inherently bad, but it demands justification through robust future growth prospects and a strong competitive advantage. One critical factor is the company's Return on Capital Employed (ROCE) of 15.14%. This indicates the efficiency with which Granules generates profits from its capital. A sustained ROCE above the cost of capital suggests a degree of economic moat, protecting them from erosion of profitability. The higher the ROCE relative to peers, the more defensible the business. However, a single metric isn't enough; a thorough understanding of the specific drivers behind the ROCE, such as manufacturing efficiency and product mix, is vital.
Comparing Granules to its peers is also crucial. While a detailed peer comparison would require a deeper dive, let’s consider the less tangible aspects.
Mankind Pharma Ltd, for example, benefits from experienced management, a key factor which can significantly influence long-term shareholder value. A careful evaluation of Granules’ management team, their track record, and their capital allocation decisions are critical for a value investor seeking to minimize downside risk. High-quality management can make a massive difference.This brief analysis is part of a more comprehensive, 80-parameter fundamental audit, verifying key assumptions, performed and verified by Sweta Mishra. It's intended for informational purposes only and uses observational language to discuss publicly available financial data. This analysis does not provide any buy or sell recommendations.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Granules India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GRANULES across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (15.14%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (20.99%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (34.33%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (34.18%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (7.43x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹782.23 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 32.00%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Granules India Ltd Financial Statements
Comprehensive financial data for Granules India Ltd including income statement, balance sheet and cash flow
About GRANULES (Granules India Ltd)
Granules India Ltd is a vertically integrated pharmaceutical company headquartered in Hyderabad, India, with a global footprint. It operates across the entire pharmaceutical value ...chain, from active pharmaceutical ingredients (APIs) to finished dosages (FDs), ensuring quality control and supply chain reliability. Granules specializes in manufacturing a diverse portfolio of essential medications, covering pain management, diabetes treatment, cough and cold remedies, and muscle relaxants. The company is renowned for its commitment to innovation, constantly striving to develop novel drug delivery systems and improve existing formulations. With a focus on sustainability and ethical business practices, Granules India Ltd is dedicated to providing affordable and accessible healthcare solutions to patients worldwide. Granules distinguishes itself through its robust manufacturing capabilities and state-of-the-art facilities, enabling the production of high-quality pharmaceutical products at scale. The company's strengths lie in its process chemistry expertise and efficient manufacturing processes, leading to cost competitiveness and timely delivery. Granules is a significant player in both the Indian and international markets, exporting its products to numerous countries across North America, Europe, Latin America, and Asia. Furthermore, the company emphasizes strategic collaborations and partnerships to expand its market reach and product offerings, solidifying its position as a trusted pharmaceutical supplier. This commitment to quality, affordability, and global reach makes Granules a vital contributor to the healthcare landscape. Granules also invests heavily in research and development, consistently seeking to improve its product portfolio and cater to unmet medical needs. Its R&D efforts focus on developing innovative formulations, improving drug efficacy, and reducing side effects. The company maintains a strong regulatory compliance record, adhering to the highest international standards and guidelines. Through its commitment to continuous improvement and innovation, Granules seeks to remain at the forefront of the pharmaceutical industry and contribute to improved patient outcomes globally. With a focus on affordability, innovation, and quality, Granules India Ltd stands as a reliable partner for healthcare providers and patients.
Company Details
Key Leadership
Corporate Events
GRANULES Share Price: Frequently Asked Questions
What is the current share price of Granules India Ltd (GRANULES)?
As of 30 Mar 2026, 12:03 pm IST, Granules India Ltd share price is ₹620.40. The GRANULES stock has a market capitalisation of ₹13.79K (Cr) on NSE/BSE.
Is GRANULES share price Overvalued or Undervalued?
GRANULES share price is currently trading at a P/E ratio of 27.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Granules India Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of GRANULES share price?
The 52-week high of GRANULES share price is ₹640.00 and the 52-week low is ₹422.00. These values are updated daily from NSE/BSE price data.
What factors affect the Granules India Ltd share price?
Key factors influencing GRANULES share price include quarterly earnings growth (Sales Growth: 34.18%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Granules India Ltd a good stock for long-term investment?
Granules India Ltd shows a 5-year Profit Growth of 8.80% and an ROE of 13.86%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.45 before investing in GRANULES shares.
How does Granules India Ltd compare with its industry peers?
Granules India Ltd competes with major peers in the Pharmaceuticals. Investors should compare GRANULES share price P/E of 27.00x and ROE of 13.86% against the industry averages to determine competitive standing.
What is the P/E ratio of GRANULES and what does it mean?
GRANULES share price has a P/E ratio of 27.00x compared to the industry average of 31.77x. Investors pay ₹27 for every ₹1 of annual earnings.
How is GRANULES performing according to Bull Run's analysis?
GRANULES has a Bull Run fundamental score of 54.2/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does GRANULES belong to?
GRANULES operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Granules India Ltd share price.
What is Return on Equity (ROE) and why is it important for GRANULES?
GRANULES has an ROE of 13.86%, which shows decent profitability but room for improvement. ROE measures how efficiently Granules India Ltd generates profits from shareholders capital.
How is GRANULES debt-to-equity ratio and what does it indicate?
GRANULES has a debt-to-equity ratio of 0.45, which indicates moderate leverage that should be monitored.
What is GRANULES dividend yield and is it a good dividend stock?
GRANULES offers a dividend yield of 0.26%, meaning you receive ₹0.26 annual dividend for every ₹100 invested in Granules India Ltd shares.
How has GRANULES share price grown over the past 5 years?
GRANULES has achieved 5-year growth rates of: Sales Growth 11.52%, Profit Growth 8.80%, and EPS Growth 9.83%.
What is the promoter holding in GRANULES and why does it matter?
Promoters hold 38.82% of GRANULES shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Granules India Ltd.
What is GRANULES market capitalisation category?
GRANULES has a market capitalisation of ₹13793 crores, placing it in the Mid-cap category.
How volatile is GRANULES stock?
GRANULES has a beta of N/A. A beta > 1 suggests the Granules India Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is GRANULES operating profit margin trend?
GRANULES has a 5-year average Operating Profit Margin (OPM) of 20.99%, indicating the company's operational efficiency.
How is GRANULES quarterly performance?
Recent quarterly performance shows Granules India Ltd YoY Sales Growth of 34.18% and YoY Profit Growth of 34.33%.
What is the institutional holding pattern in GRANULES?
GRANULES has FII holding of 14.09% and DII holding of 17.91%. Significant institutional holding often suggests professional confidence in the Granules India Ltd stock.